CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,244,783
- in 2 filings, $3.2M under 10b5-1 plans
Net −$3,244,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-01 | Aguilar-Cordova Estuardo 10% owner | Sale | +6,214 | $7.01 | $44K | 988,661 |
| 2024-07-17 | Tyagarajan Seshu Chief Technology Officer | Sale | −14,851 | $6.47 | $96K | 146,049 |
| 2024-07-17 | Tak Paul Peter Chief Executive Officer | Sale | −22,528 | $6.47 | $146K | 330,735 |
| 2024-07-17 | Schoch Charles See Remarks | Sale | −9,884 | $6.47 | $64K | 62,520 |
| 2024-07-17 | Nichols William Garrett Chief Medical Officer | Sale | −10,875 | $6.47 | $70K | 114,482 |
| 2024-07-17 | Barone Francesca Chief Scientific Officer | Sale | −14,051 | $6.47 | $91K | 159,961 |
| 2024-07-11 | Tyagarajan Seshu Chief Technology Officer | Sale | −13,330 | $5.97 | $80K | 160,900 |
| 2024-07-11 | Tak Paul Peter Chief Executive Officer | Sale | −20,293 | $5.97 | $121K | 353,263 |
| 2024-07-11 | Schoch Charles See Remarks | Sale | −8,897 | $5.97 | $53K | 72,404 |
| 2024-07-11 | Nichols William Garrett Chief Medical Officer | Sale | −9,769 | $5.97 | $58K | 125,357 |
| 2024-07-11 | Barone Francesca Chief Scientific Officer | Sale | −12,645 | $5.97 | $76K | 174,012 |
| 2024-06-26 | PAPA JOSEPH C Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2024-06-26 | Nguyen Diem Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2024-06-26 | Nabel Gary J. Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2024-06-26 | Martell Christopher Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2024-06-26 | Manning Paul B Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2024-06-26 | Loggia Nicoletta Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2024-06-26 | Gaeta Renee Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2024-06-26 | Benz Edward J. JR Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2023-11-28 | Tak Paul Peter Chief Executive Officer | Shares withheld for taxes | −43,443 | $0.90 | $39K | 373,556 |
Page 8 of 13 · 249 trades